1-6 of 6
Brian K. Link
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression

Nicholas Borcherding, Andrew P. Voigt, Vincent Liu, Brian K. Link, Weizhou Zhang, Ali Jabbari
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (10): 2996–3005.
https://doi.org/10.1158/1078-0432.CCR-18-3309
Published: 15 May 2019
View article titled, Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression
Open the PDF for Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression in another window
Includes: Supplementary data
Journal Articles

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy

Laura M. Rogers, Sarah L. Mott, Brian J. Smith, Brian K. Link, Deniz Sahin, George J. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 954–961.
https://doi.org/10.1158/1078-0432.CCR-16-1275
Published: 14 February 2017
View article titled, Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Open the PDF for Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy in another window
Includes: Supplementary data
Journal Articles

Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma

Preethi Reddy Marri, Lucy S. Hodge, Matthew J. Maurer, Steven C. Ziesmer, Susan L. Slager, Thomas M. Habermann, Brian K. Link, James R. Cerhan, Anne J. Novak, Stephen M. Ansell
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6812–6819.
https://doi.org/10.1158/1078-0432.CCR-13-1879
Published: 16 December 2013
View article titled, Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma
Open the PDF for Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma in another window
Journal Articles

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

Andres Forero-Torres, Sven de Vos, Brad L. Pohlman, Maksim Pashkevich, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, James G. Nelson, Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, Kristen N. Ganjoo
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1395–1403.
https://doi.org/10.1158/1078-0432.CCR-11-0850
Published: 01 March 2012
View article titled, Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Open the PDF for Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Emilian Racila, Brian K. Link, Wen-Kai Weng, Thomas E. Witzig, Stephen Ansell, Matthew J. Maurer, Jian Huang, Christopher Dahle, Ahmad Halwani, Ronald Levy, George J. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6697–6703.
https://doi.org/10.1158/1078-0432.CCR-08-0745
Published: 16 October 2008
View article titled, A Polymorphism in the Complement Component <em>C1qA</em> Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Open the PDF for A Polymorphism in the Complement Component <em>C1qA</em> Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma in another window
Journal Articles

Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma

John P. Leonard, Brian K. Link, Christos Emmanouilides, Stephanie A. Gregory, Daniel Weisdorf, Jeffrey Andrey, John Hainsworth, Joseph A. Sparano, Donald E. Tsai, Sandra Horning, Arthur M. Krieg, George J. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (20): 6168–6174.
https://doi.org/10.1158/1078-0432.CCR-07-0815
Published: 18 October 2007
View article titled, Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma
Open the PDF for Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma in another window